Have a feature idea you'd love to see implemented?
Let us know!
LXRX Lexicon Pharmaceuticals Inc
Price (delayed)
$0.7717
Market cap
$278.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.75
Enterprise value
$344.31M
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes
Highlights
The company's gross profit rose by 45% QoQ
LXRX's revenue is up by 44% from the previous quarter
Lexicon Pharmaceuticals's quick ratio has decreased by 35% from the previous quarter but it has increased by 7% YoY
Lexicon Pharmaceuticals's equity has increased by 28% YoY but it has decreased by 26% QoQ
The net income has decreased by 37% YoY and by 7% from the previous quarter
Lexicon Pharmaceuticals's gross margin has decreased by 3.8% YoY
Key stats
What are the main financial stats of LXRX
Market
Valuations
Earnings
Shares outstanding
361.49M
Market cap
$278.96M
Enterprise value
$344.31M
Price to book (P/B)
1.56
Price to sales (P/S)
53.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
65.85
Revenue
$5.23M
EBIT
-$199.25M
EBITDA
-$198.7M
Free cash flow
-$208.39M
Per share
Balance sheet
Liquidity
EPS
-$0.75
Free cash flow per share
-$0.58
Book value per share
$0.49
Revenue per share
$0.01
TBVPS
$0.77
Total assets
$321.12M
Total liabilities
$142.61M
Debt
$99.9M
Equity
$178.51M
Working capital
$232.56M
Debt to equity
0.56
Current ratio
7.45
Quick ratio
7.25
Net debt/EBITDA
-0.33
Margins
Efficiency
Dividend
EBITDA margin
-3,799.9%
Gross margin
93.5%
Net margin
-4,138.3%
Operating margin
-4,037.4%
Return on assets
-64.5%
Return on equity
-108.1%
Return on invested capital
-63.3%
Return on capital employed
-69.9%
Return on sales
-3,810.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LXRX stock price
How has the Lexicon Pharmaceuticals stock price performed over time
Intraday
-4.42%
1 week
-27.2%
1 month
-60.43%
1 year
-28.55%
YTD
-49.56%
QTD
-50.85%
Financial performance
How have Lexicon Pharmaceuticals's revenue and profit performed over time
Revenue
$5.23M
Gross profit
$4.89M
Operating income
-$211.12M
Net income
-$216.39M
Gross margin
93.5%
Net margin
-4,138.3%
LXRX's operating margin has surged by 86% year-on-year and by 25% since the previous quarter
LXRX's net margin has surged by 86% year-on-year and by 25% since the previous quarter
The company's gross profit rose by 45% QoQ
LXRX's revenue is up by 44% from the previous quarter
Growth
What is Lexicon Pharmaceuticals's growth rate over time
Valuation
What is Lexicon Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.56
P/S
53.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
65.85
The company's EPS rose by 3.8% QoQ and by 2.6% YoY
The P/B is 55% lower than the 5-year quarterly average of 3.5 and 42% lower than the last 4 quarters average of 2.7
Lexicon Pharmaceuticals's equity has increased by 28% YoY but it has decreased by 26% QoQ
LXRX's price to sales (P/S) is 94% less than its 5-year quarterly average of 941.7 and 73% less than its last 4 quarters average of 197.0
LXRX's revenue is up by 44% from the previous quarter
Efficiency
How efficient is Lexicon Pharmaceuticals business performance
The company's return on sales has surged by 86% YoY and by 25% QoQ
LXRX's ROIC is up by 16% YoY but it is down by 5% from the previous quarter
The company's return on equity rose by 9% YoY
LXRX's ROA is down by 3.4% QoQ but it is up by 3% YoY
Dividends
What is LXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LXRX.
Financial health
How did Lexicon Pharmaceuticals financials performed over time
The total assets is 125% greater than the total liabilities
Lexicon Pharmaceuticals's quick ratio has decreased by 35% from the previous quarter but it has increased by 7% YoY
The current ratio has contracted by 35% from the previous quarter but it has grown by 8% YoY
LXRX's debt is 44% smaller than its equity
Lexicon Pharmaceuticals's debt to equity has increased by 37% QoQ but it has decreased by 25% YoY
Lexicon Pharmaceuticals's equity has increased by 28% YoY but it has decreased by 26% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.